NCT03942094Unknown3 期
Efficacy and Safety of Nilotinib as the First-line Treatment for Patients With Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia: a Prospective Study
Shenzhen Second People's Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2019年6月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Molecular response (MR) 4.5 at 18 months of nilotinib 300 mg twice a day
研究概览
简要总结
This is a phase IIIb, multi-centre, single-arm, open-label, prospective study investigating the efficacy and safety of nilotinib as the first-line treatment for the adult patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) in China. Nilotinib 300 mg BID will be provided in this study. The assessment for the primary efficacy endpoint will be performed at 18 months and the rate of patients obtaining MR4.5 will be measured at this time point. Secondary endpoints include the complete hematologic response(CHR) and the rates of major molecular reactions (MMR) by 3, 6, 9,12,18 and 24 months; event free survival (EFS); overall survival (OS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients
- •Newly diagnosed CP-CML within 6 months prior to study entry, positive Philadelphia chromosome or positive BCR-ABL (M-bcr transcript)
- •Age ≥ 18 years old (no upper age limit given)
- •CML-CP defined by primordial cells in peripheral blood or bone marrow <20%, basophils in peripheral blood <20%, platelets ≥100 x 109/L(≥100,000/mm3), except for hepatosplenomegaly
- •Patient for whom treatment with Imatinib within 2 weeks is expected No other CML treatment except for hydroxyurea and/or anagrelide and/or IFN ECOG score 0 to 2
- •Organ function defined by total serum bilirubin levels < 1.5 × the upper limit of the normal range (ULN), SGOT and SGPT < 2.5 UNL, creatinine < 1.5 × ULN, amylase and lipase ≤ 1.5 × ULN and alkaline phosphatase ≤ 2.5 × ULN not directly related to the CML
- •Laboratory values defined by potassium ≥ LLN, magnesium ≥ LLN, phosphate ≥ LLN, total calcium (correction for serum albumin) ≥ LLN
- •No planned allogeneic stem cell transplantation
- •Signed informed consent
排除标准
- •Patients confirmed to have a T315I mutation
- •TKIs are not allowed to be treated prior to entering the study, unless the patient has an emergency pending the start of the study, and any dose of commercial imatinib may be used to the patient, but no more than 2 weeks
- •Treatment with IFN for more than 3 mouths
- •Impaired cardiac function including any of the following:
- •Complete left bundle branch block
- •Right bundle branch block plus left anterior hemiblock,bifascicular block
- •Use of a ventricular-paced pacemaker
- •Congenital long QT syndrome
- •Clinically significant ventricular or atrial tachyarrhythmias
- •Clinically significant resting bradycardia (<50 beats per minute)
- •QTcF >450 msec on screening ECG.If QTcF >450 msec and electrolytes are not within normal ranges before nilotinib dosing, electrolytes should be corrected and then the patient rescreened for QTcF criterion
- •Myocardial infarction within 12 months prior to starting nilotinib
- •Other clinical significant heart disease (e.g. unstable angina,congestive heart failure,uncontrolled hypertension)
- •Patients who are confirmed CNS infiltration by cytopathology
- •Concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infections)
- •Congenital or acquired bleeding tendency
- •Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- •Received other study medications within 30 days (defined as drugs that cannot be used based on approved indications)
- •Patients unwilling or unable to comply with the protocol
- •Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention
- •Concomitant medications known to be strong inducers or inhibitors of the CYP450 Isoenzyme CYP3A4 (for example, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, and midazolam)
- •Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g.ulcerative disease,uncontrolled nausea,vomiting and diarrhea,malabsorption syndrome,small bowel resection or gastric by-pass surgery)
- •History of acute pancreatitis within 12 months or chronic pancreatitis
- •History of acute or chronic diseases of Liver, pancreas or kidney
- •Concomitant medications with potential QT prolongation
- •Patients who are pregnant or breast feeding or women of reproductive potential not employing an effective method of birth control.Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to administration of nilotinib.Post menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential.Female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug
研究组 & 干预措施
Nilotinib
Experimental
干预措施: Nilotinib (Drug)
结局指标
主要结局
Molecular response (MR) 4.5 at 18 months of nilotinib 300 mg twice a day
时间窗: 18 months
次要结局
- Rate of CCyR (complete cytogenetic responses: bone marrow Philadelphie positive at 0 % on at least 20 metaphases) at 3, 6, 9, 12, 24 months of nilotinib.(24 months)
- Major Molecular Response at 3, 6, 9, 12, 24 months of nilotinib(24 months)
- Event-free survival(24 months)
- Overall survival(24 months)
- Molecular Response 4.5 at 3, 6, 9, 12, 24 months of nilotinib(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Nilotinib in the Treatment of Systemic SclerosisSystemic SclerosisNCT01166139Hospital for Special Surgery, New York10
终止
2 期
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationRenal Cell CarcinomaNCT02626754vghtpe user13
终止
1 期
Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT01222143University Health Network, Toronto12
已完成
1 期
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic Phase Chronic Myelogenous LeukemiaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Chronic Myelogenous LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaPhiladelphia Positive Adult Acute Lymphoblastic LeukemiaPhiladelphia Positive Childhood Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRelapsing Chronic Myelogenous LeukemiaUntreated Adult Acute Lymphoblastic LeukemiaUntreated Childhood Acute Lymphoblastic LeukemiaNCT00702403Fred Hutchinson Cancer Center40
已完成
3 期
Nilotinib in PH+, BCR-, ABL+ CML PatientsChronic Myeloid LeukemiaNCT01535391Gruppo Italiano Malattie EMatologiche dell'Adulto109